Sinaptica Therapeutics
Ken Mariash has a diverse and extensive work experience. Ken is currently the CEO of Sinaptica Therapeutics, a company developing closed-loop neuromodulation therapy for Alzheimer's. Prior to this, Ken was the Founder & Managing Partner of Rubicon Strategy Partners, LLC, where they helped leadership make important investment decisions. Ken also worked as the Vice President of Marketing at EBT Medical, Inc., overseeing all commercial aspects of the company's neurostimulator and companion app. Ken gained significant experience at Boston Scientific Neuromodulation, where they served as the Director of Strategy and New Markets, and was involved in various acquisitions and strategic planning. Previously, they held leadership roles at Baxter BioScience, CSL Behring, Charles River Associates, and Harvard Business School.
Ken Mariash attended Brown University, where they studied Biochemistry and Business Economics, focusing on the field of Business/Managerial Economics. The start and end years of their education are not specified.
This person is not in any teams
This person is not in any offices
Sinaptica Therapeutics
Sinaptica Therapeutics™ is a Cambridge MA-based, clinical-stage company that has developed a personalized closed-loop neuromodulation therapy for Alzheimer’s Disease (AD). The company was founded by two top clinical researchers in the field of noninvasive brain modulation for neurodegenerative disorders, together with support from biotech, digital health, and medical device industry executives. The company’s SinaptiStim™ System represents a totally new approach to treating AD by enhancing neuroplasticity via neurostimulation of key brain networks involved in memory, and has been granted FDA Breakthrough Designation based on unprecedented published Phase 2 sham-controlled data that achieved statistical significance on all four gold-standard cognitive & functional clinical endpoints. Sinaptica is building upon over a decade of research on innovative brain targeting methods, biophysical modeling, and noninvasive treatment protocols leveraging machine learning on proprietary datasets to create a foundational leap in personalized precision electromagnetic therapeutics. Based on highly significant published sham-controlled data, the company's neurostimulation device and integrated personalization engine has the potential to become one of the most clinically-effective treatments to reach Alzheimer’s patients in over two decades, and is protected by multiple pending patents.